Field evaluation of a broadly sensitive HIV-1 In-house genotyping assay for use with both plasma and dried blood spot specimens in a resource-limited country

Journal of Clinical Microbiology

Volumn 51, Issue 2, 2013, Pages 529-539

  Inzaule, Seth ^a   Yang, Chunfu ^c   Kasembeli, Alex ^a   Nafisa, Lillian ^a   Okonji, Jully ^a   Oyaro, Boaz ^a   Lando, Richard ^a   Mills, Lisa A ^b   Laserson, Kayla ^b   Thomas, Timothy ^b   Nkengasong, John ^c   Zeh, Clement ^b  

^a Centre for Global Health Research   (Kenya)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; ARTICLE; CHILD; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DRIED BLOOD SPOT TESTING; DRUG EFFICACY; FEMALE; GENE MUTATION; GENOTYPING TECHNIQUE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PREDICTIVE VALUE; PRIORITY JOURNAL; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS; VERTICAL TRANSMISSION; VIRUS LOAD;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; GENOME, VIRAL; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; PHENOTYPE; PROVIRUSES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; VIRAL LOAD; VIRUS REPLICATION;

EID: 84873029466     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02347-12     Document Type: Article

References (50)

1. Global Fund To Fight AIDS, Tuberculosis and Malaria. 2009. Scaling up for impact: results report. Executive summary. Global Fund To Fight AIDS, Tuberculosis and Malaria, Geneva, Switzerland.
2. PEPFAR. 2009. Celebrating life: fifth annual report to Congress on PEPFAR. The United States President's Emergency Plan for AIDS Relief, Washington, DC.
3. UNAIDS. 2008. 2008 report on the global AIDS epidemic. UNAIDS, Geneva, Switzerland.
4. WHO, UNAIDS, UNICEF. 2009. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. September 2009 progress report. WHO, Geneva, Switzerland.
5. Bertagnolio S, Derdelinckx I, Parker M, Fitzgibbon J, Fleury H, Peeters M, Schuurman R, Pillay D, Morris L, Tanuri A, Gershy-Damet GM, Nkengasong J, Gilks CF, Sutherland D, Sandstrom P. 2008. World Health Organization/HIVResNet drug resistance laboratory strategy. Antivir. Ther. 13(Suppl. 2):49 -57.
6. Hammer SM, Eron JJ Jr, Reiss P, Schooley RT, Thompson MA, Walmsley S, Cahn P, Fischl MA, Gatell JM, Hirsch MS, Jacobsen DM, Montaner JS, Richman DD, Yeni PG, Volberding PA. 2008. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 300:555-570.
7. Hirsch MS, Conway B, D'Aquila RT, Johnson VA, Brun-Vezinet F, Clotet B, Demeter LM, Hammer SM, Jacobsen DM, Kuritzkes DR, Loveday C, Mellors JW, Vella S, Richman DD. 1998. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society-USA panel. JAMA 279:1984- 1991.
8. Birx D, de Souza M, Nkengasong JN. 2009. Laboratory challenges in the scaling up of HIV, TB, and malaria programs: the interaction of health and laboratory systems, clinical research, and service delivery. Am. J. Clin. Pathol. 131:849-851.
9. Martinson N, Mohapi L, Bakos D, Gray GE, McIntyre JA, Holmes CB. 2009. Costs of providing care for HIV-infected adults in an urban HIV clinic in Soweto, South Africa. J. Acquir. Immune Defic. Syndr. 50:327- 330.
10. Cecelia AJ, Balakrishnan P, Mohanakrishnan, Venkatakrishnan B, Solomon S, Kumarasamy N. 2006. Effective evaluation of novel low-cost CD4 monitoring assays. J. Immunol. Methods 316:158 -162.
11. Fiscus SA, Cheng B, Crowe SM, Demeter L, Jennings C, Miller V, Respess R, Stevens W. 2006. HIV-1 viral load assays for resource-limited settings. PLoS Med. 3:e417. doi:10.1371/journal.pmed.0030417.
12. Jani IV, Sitoe NE, Chongo PL, Alfai ER, Quevedo JI, Tobaiwa O, Lehe JD, Peter TF. 2011. Accurate CD4 T-cell enumeration and antiretroviral drug toxicity monitoring in primary healthcare clinics using point-of-care testing. AIDS 25:807- 812.
13. Masciotra S, Garrido C, Youngpairoj AS, McNulty A, Zahonero N, Corral A, Heneine W, de Mendoza C, Garcia-Lerma JG. 2007. High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients. AIDS 21:2503-2511.
14. Murtagh MM. 2011. UNITAID technical report: HIV/AIDS diagnostic landscape, 2nd ed. UNITAID, Geneva, Switzerland.
15. Mehta N, Trzmielina S, Nonyane BA, Eliot MN, Lin R, Foulkes AS, McNeal K, Ammann A, Eulalievyolo V, Sullivan JL, Luzuriaga K, Somasundaran M. 2009. Low-cost HIV-1 diagnosis and quantification in dried blood spots by real time PCR. PLoS One 4:e5819. doi:10.1371/journal.pone.0005819.
16. Greengrass V, Plate MM, Steele PM, Taqi R, van Rooijen L, Sun Y, Morris LM, Crowe SM. 2007. HIV monitoring in laboratories in resource limited areas. J. Chin. Clin. Med. 2:469-480.
17. Bennett DE, Bertagnolio S, Sutherland D, Gilks CF. 2008. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir. Ther. 13(Suppl. 2):1-13.
18. Bergeron M, Daneau G, Ding T, Sitoe NE, Westerman LE, Stokx J, Jani IV, Coetzee LM, Scott L, De Weggheleire A, Boel L, Stevens WS, Glencross DK, Peter TF. 2012. Correction: performance of the PointCare NOWsystem for CD4 counting in HIV patients based on five independent evaluations. PLoS One 7(9). doi:10.1371/annotation/71a6d947-c034 -4749-a33d-971284ea3408.
19. Bertagnolio S, Sutherland D. 2005. WHO approach to track HIV drug resistance emergence and transmission in countries scaling up HIV treatment. AIDS 19:1329 -1330.
20. Bennett DE, Myatt M, Bertagnolio S, Sutherland D, Gilks CF. 2008. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir. Ther. 13(Suppl. 2): 25-36.
21. Cochrane J. 2000. Narrowing the gap: access to HIV treatments in developing countries. A pharmaceutical company's perspective. J. Med. Ethics 26:47-50.
22. Crowe S, Turnbull S, Oelrichs R, Dunne A. 2003. Monitoring of human immunodeficiency virus infection in resource-constrained countries. Clin. Infect. Dis. 37:S25-S35.
23. Jagodzinski LL, Cooley JD, Weber M, Michael NL. 2003. Performance characteristics of human immunodeficiency virus type 1 (HIV-1) genotyping systems in sequence-based analysis of subtypes other than HIV-1 subtype B. J. Clin. Microbiol. 41:998 -1003.
24. Saravanan S, Vidya M, Balakrishnan P, Kumarasamy N, Solomon SS, Solomon S, Kantor R, Katzenstein D, Ramratnam B, Mayer KH. 2009. Evaluation of two human immunodeficiency virus-1 genotyping systems: ViroSeq 2.0 and an in-house method. J. Virol. Methods 159:211-216.
25. Hallack R, Doherty LE, Wethers JA, Parker MM. 2008. Evaluation of dried blood spot specimens for HIV-1 drug-resistance testing using the Trugene HIV-1 genotyping assay. J. Clin. Virol. 41:283-287.
26. Parkin N, Diallo K, Parry CR, Mwebaza S, Batamwita R, Devos J, Bbosa B, Lyaboga F, Magambo B, Jordan M, Downing R, Kaleebu P, Yang C, Bertagnolio S. 2012. Field study of the utility of dried blood spots (DBS) for HIV-1 drug resistance (HIVDR) genotyping in Kampala, Uganda: storage for 2 weeks and shipping at ambient temperature has no effect on genotyping efficiency. International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies, vol. 17. International Medical Press, Melia Sitges, Spain.
27. WHO. 2010. Guidance on regulations for the transport of infectious substances 2011-2012. WHO/HSE/IHR/2010.8. WHO, Geneva, Switzerland.
28. Buckton AJ, Bissett SL, Myers RE, Beddows S, Edwards S, Cane PA, Pillay D. 2008. Development and optimization of an internally controlled dried blood spot assay for surveillance of human immunodeficiency virus type-1 drug resistance. J. Antimicrob. Chemother. 62:1191-1198.
29. McNulty A, Jennings C, Bennett D, Fitzgibbon J, Bremer JW, Ussery M, Kalish ML, Heneine W, Garcia-Lerma JG. 2007. Evaluation of dried blood spots for human immunodeficiency virus type 1 drug resistance testing. J. Clin. Microbiol. 45:517-521.
30. Parkin N, de Mendoza C, Schuurman R, Jennings C, Bremer J, Jordan MR, Bertagnolio S. 2012. Evaluation of in-house genotyping assay performance using dried blood spot specimens in the Global World Health Organization laboratory network. Clin. Infect. Dis. 54(Suppl 4):S273- S279.
31. WHO. 2010. WHO manual for HIV drug resistance testing using dried blood spots specimens. WHO, Geneva, Switzerland.
32. Yang C, McNulty A, Diallo K, Zhang J, Titanji B, Kassim S, Wadonda- Kabondo N, Aberle-Grasse J, Kibuka T, Ndumbe PM, Vedapuri S, Zhou Z, Chilima B, Nkengasong JN. 2010. Development and application of a broadly sensitive dried-blood-spot-based genotyping assay for global surveillance of HIV-1 drug resistance. J. Clin. Microbiol. 48:3158 -3164.
33. Zhou Z, Wagar N, DeVos JR, Rottinghaus E, Diallo K, Nguyen DB, Bassey O, Ugbena R, Wadonda-Kabondo N, McConnell MS, Zulu I, Chilima B, Nkengasong J, Yang C. 2011. Optimization of a low cost and broadly sensitive genotyping assay for HIV-1 drug resistance surveillance and monitoring in resource-limited settings. PLoS One 6:e28184. doi:10 .1371/journal.pone.0028184.
34. Thomas TK, Masaba R, Borkowf CB, Ndivo R, Zeh C, Misore A, Otieno J, Jamieson D, Thigpen MC, Bulterys M, Slutsker L, De Cock KM, Amornkul PN, Greenberg AE, Fowler MG. 2011. Triple-antiretroviral prophylaxis to prevent mother-to-child HIV transmission through breastfeeding-the Kisumu Breastfeeding Study, Kenya: a clinical trial. PLoS Med. 8:e1001015. doi:10.1371/journal.pmed. 1001015.
35. Eshleman SH, Crutcher G, Petrauskene O, Kunstman K, Cunningham SP, Trevino C, Davis C, Kennedy J, Fairman J, Foley B, Kop J. 2005. Sensitivity and specificity of the ViroSeq human immunodeficiency virus type 1 (HIV-1) genotyping system for detection of HIV-1 drug resistance mutations by use of an ABI PRISM 3100 genetic analyzer. J. Clin. Microbiol. 43:813- 817.
36. Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, Shafer R, Wensing AM, Richman DD. 2011. 2011 update of the drug resistance mutations in HIV-1. Top. Antivir. Med. 19:156 -164.
37. Tamura K, Dudley J, Nei M, Kumar S. 2007. MEGA4: molecular evolutionary genetics analysis (MEGA) software version 4.0. Mol. Biol. Evol. 24:1596 -1599.
38. Buderer NM. 1996. Statistical methodology: I. Incorporating the prevalence of disease into the sample size calculation for sensitivity and specificity. Acad. Emerg. Med. 3:895-900.
39. Steegen K, Luchters S, Dauwe K, Reynaerts J, Mandaliya K, Jaoko W, Plum J, Temmerman M, Verhofstede C. 2009. Effectiveness of antiretroviral therapy and development of drug resistance in HIV-1 infected patients in Mombasa, Kenya. AIDS Res. Ther. 6:12. doi:10.1186/1742 -6405-6-12.
40. WHO. 2010. Sequence quality assessment tool (SQUAT). WHO, Geneva, Switzerland.
41. Swofford DL. 2003. PAUP*. Phylogenetic analysis using parsimony (*and other methods), version 4. Sinauer Associates, Sunderland, MA.
42. Johannessen A. 2010. Dried blood spots in HIV monitoring: applications in resource-limited settings. Bioanalysis 2:1893-1908.
43. Johannessen A, Garrido C, Zahonero N, Sandvik L, Naman E, Kivuyo SL, Kasubi MJ, Gundersen SG, Bruun JN, de Mendoza C. 2009. Dried blood spots perform well in viral load monitoring of patients who receive antiretroviral treatment in rural Tanzania. Clin. Infect. Dis. 49:976 -981.
44. Johannessen A, Troseid M, Calmy A. 2009. Dried blood spots can expand access to virological monitoring of HIV treatment in resourcelimited settings. J. Antimicrob. Chemother. 64:1126 -1129.
45. Lira R, Valdez-Salazar H, Vazquez-Rosales G, Rojas-Montes O, Ruiz-Tachiquin M, Torres-Ibarra R, Cano-Dominguez C, Maldonado-Rodriguez A, Gomez A, Munoz O, Alvarez-Munoz MT. 2010. Genotypic testing for HIV-1 drug resistance using dried blood samples. Arch. Virol. 155:1117-1125.
46. Youngpairoj AS, Masciotra S, Garrido C, Zahonero N, de Mendoza C, Garcia-Lerma JG. 2008. HIV-1 drug resistance genotyping from dried blood spots stored for 1 year at 4 degrees C. J. Antimicrob. Chemother. 61:1217-1220.
47. Jordan MR, Bennett DE, Bertagnolio S, Gilks CF, Sutherland D. 2008. World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites. Antivir. Ther. 13(Suppl. 2):15-23.
48. Kandathil AJ, Ramalingam S, Kannangai R, David S, Sridharan G. 2005. Molecular epidemiology of HIV. Indian J. Med. Res. 121:333-344.
49. Nkengasong JN, Adje-Toure C, Weidle PJ. 2004. HIV antiretroviral drug resistance in Africa. AIDS Rev. 6:4 -12.
50. Peeters M, Toure-Kane C, Nkengasong JN. 2003. Genetic diversity of HIV in Africa: impact on diagnosis, treatment, vaccine development and trials. AIDS 17:2547-2560.